Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Peter Norman. (2015) Orphan drug approvals of 2014: Europe and the United States. Expert Opinion on Orphan Drugs 3:4, pages 445-455.
Read now
Read now
Alessia Carocci, Alessia Catalano & Maria Stefania Sinicropi. (2014) Melatonergic drugs in development. Clinical Pharmacology: Advances and Applications 6, pages 127-137.
Read now
Read now
Ludovit Paulis, Fedor Simko & Moshe Laudon. (2012) Cardiovascular effects of melatonin receptor agonists. Expert Opinion on Investigational Drugs 21:11, pages 1661-1678.
Read now
Read now
Articles from other publishers (15)
Younggi Choi & Brian K. Raymer. (2019) Sleep modulating agents. Bioorganic & Medicinal Chemistry Letters 29:16, pages 2025-2033.
Crossref
Crossref
Hans-Peter Landolt, Sebastian C. Holst & Amandine Valomon. 2019. Sleep-Wake Neurobiology and Pharmacology. Sleep-Wake Neurobiology and Pharmacology
207
241
.
Daniel J. Buysse & Shachi Tyagi. 2017. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
432
445.e7
.
Sebastian C. HolstAmandine ValomonHans-Peter Landolt. (2016) Sleep Pharmacogenetics: Personalized Sleep-Wake Therapy. Annual Review of Pharmacology and Toxicology 56:1, pages 577-603.
Crossref
Crossref
Trevor R. Norman. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
229
247
.
Caitlin Murphy, Nathalie Duponsel, Xi Sheila Huang, Walter Wittich, Robert K. Koenekoop & Olga Overbury. (2015) Retinal Disorders and Sleep Disorders: Are They Genetically Related?. Journal of Visual Impairment & Blindness 109:5, pages 359-370.
Crossref
Crossref
David N. Neubauer, Ahmed S. BaHammam & Seithikurppu R. Pandi-Perumal. 2015. Drug Treatment of Sleep Disorders. Drug Treatment of Sleep Disorders
261
269
.
Darius. P. Zlotos, Ralf Jockers, Erika Cecon, Silvia Rivara & Paula A. Witt-Enderby. (2013)
MT
1
and MT
2
Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential
. Journal of Medicinal Chemistry 57:8, pages 3161-3185.
Crossref
Crossref
Katie S. Adams & Ericka L. Breden Crouse. (2014) Melatonin agonists in the management of sleep disorders: A focus on ramelteon and tasimelteon. Mental Health Clinician 4:2, pages 59-64.
Crossref
Crossref
M. Dresler, V.I. Spoormaker, P. Beitinger, M. Czisch, M. Kimura, A. Steiger & F. Holsboer. (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacology & Therapeutics 141:3, pages 300-334.
Crossref
Crossref
Rafael Ochoa-Sanchez, Stefano Comai, Gilberto Spadoni, Annalida Bedini, Giorgio Tarzia & Gabriella Gobbi. (2014) Melatonin, selective and non-selective MT1/MT2 receptors agonists: Differential effects on the 24-h vigilance states. Neuroscience Letters 561, pages 156-161.
Crossref
Crossref
Darius P. Zlotos. 2014. Melatonin and Melatonergic Drugs in Clinical Practice. Melatonin and Melatonergic Drugs in Clinical Practice
97
116
.
Amnon Brzezinski. 2014. Melatonin and Melatonergic Drugs in Clinical Practice. Melatonin and Melatonergic Drugs in Clinical Practice
263
273
.
Laurence Morellato, Marie Lefas-Le Gall, Michel Langlois, Daniel-Henri Caignard, Pierre Renard, Philippe Delagrange & Monique Mathé-Allainmat. (2013) Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors. Bioorganic & Medicinal Chemistry Letters 23:2, pages 430-434.
Crossref
Crossref
Daniel P. Cardinali, Venkataramanujan Srinivasan, Amnon Brzezinski & Gregory M. Brown. (2012) Melatonin and its analogs in insomnia and depression. Journal of Pineal Research 52:4, pages 365-375.
Crossref
Crossref